Use of proteolysis resistant active VEGF
    1.
    发明授权
    Use of proteolysis resistant active VEGF 失效
    使用蛋白水解抗性活性VEGF

    公开(公告)号:US08168590B2

    公开(公告)日:2012-05-01

    申请号:US12349531

    申请日:2009-01-07

    IPC分类号: A61K38/18 C07K14/475

    CPC分类号: C07K14/52 A61K38/1866

    摘要: The invention relates to vascular endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

    摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的血管内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。

    Proteolysis resistant active vegf
    2.
    发明申请
    Proteolysis resistant active vegf 失效
    蛋白水解抗性活性蔬菜

    公开(公告)号:US20060148687A1

    公开(公告)日:2006-07-06

    申请号:US10506893

    申请日:2003-03-06

    IPC分类号: A61K38/18 C07K14/475

    CPC分类号: C07K14/52 A61K38/1866

    摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

    摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。

    Proteolysis Resistant Active VEGF
    3.
    发明申请
    Proteolysis Resistant Active VEGF 审中-公开
    蛋白水解抗性活性VEGF

    公开(公告)号:US20120258915A1

    公开(公告)日:2012-10-11

    申请号:US13445016

    申请日:2012-04-12

    IPC分类号: A61K38/18 A61P17/02

    CPC分类号: C07K14/52 A61K38/1866

    摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

    摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。

    Proteolysis resistant active VEGF
    5.
    发明授权
    Proteolysis resistant active VEGF 失效
    蛋白水解抗性活性VEGF

    公开(公告)号:US07491696B2

    公开(公告)日:2009-02-17

    申请号:US10506893

    申请日:2003-03-06

    CPC分类号: C07K14/52 A61K38/1866

    摘要: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

    摘要翻译: 本发明涉及其中AA位置111处的丙氨酸被脯氨酸替代的内皮生长因子(VEGF)。 AA位置110处的精氨酸可另外被另一氨基酸替代。 本发明还涉及根据本发明的VEGF的衍生物,核酸,表达系统,药物以及本发明的VEGF突变体用于治疗慢性伤口的用途。